Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis

Company Overview

Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S. Food and Drug Administration approval in 2022 for the treatment of amyotrophic lateral sclerosis (ALS). Amylyx has also filed for regulatory approval of AMX0035 (known as Albrioza) in the European Union and continues to explore its potential utility in other neurodegenerative disorders. In addition to ALS, the Amylyx pipeline includes early-stage programs investigating therapies for Alzheimer’s disease and GM1 gangliosidosis, reflecting the company’s broader commitment to addressing central nervous system pathologies.

Amylyx operates primarily in North America and is advancing its global development and commercialization capabilities through strategic collaborations and regulatory engagements. Under the leadership of Chief Executive Officer John H. Johnson III, the company continues to expand clinical development efforts and strengthen its manufacturing and distribution networks. Amylyx’s multidisciplinary team of scientists, clinicians and regulatory experts works to translate preclinical discoveries into potential therapies for patients facing critical neurological challenges.

Key Stats

• Today's Range: $14.40 to $15.25
• 50-Day Range: $7.82 to $15.79
• 52-Week Range: $2.60 to $15.94
• Volume: 1.88 million shs
• Average Volume: 1.90 million shs
• Market Capitalization: $1.33 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.75
• Consensus Rating: Moderate Buy

Amylyx Pharmaceuticals Stock Analysis - MarketRank™

Amylyx Pharmaceuticals scored higher than 54% of companies evaluated by MarketBeat, and ranked 506th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Amylyx Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 9 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Amylyx Pharmaceuticals has a consensus price target of $16.75, representing about 12.0% upside from its current price of $14.95.

Amount of Analyst Coverage

Amylyx Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Amylyx Pharmaceuticals are expected to grow in the coming year, from ($2.20) to ($1.36) per share.

Price to Book Value per Share Ratio

Amylyx Pharmaceuticals has a P/B Ratio of 6.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.64% of the float of Amylyx Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Amylyx Pharmaceuticals has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Amylyx Pharmaceuticals has recently increased by 14.82%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Amylyx Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Amylyx Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.64% of the float of Amylyx Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Amylyx Pharmaceuticals has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Amylyx Pharmaceuticals has recently increased by 14.82%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.66

News Sentiment

Amylyx Pharmaceuticals has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Amylyx Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

34 people have searched for AMLX on MarketBeat in the last 30 days. This is an increase of 240% compared to the previous 30 days.

MarketBeat Follows

2 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Amylyx Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,319,495.00 in company stock.

Percentage Held by Insiders

12.30% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.84% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AMLX Stock Analysis - Frequently Asked Questions

How have AMLX shares performed this year?

Amylyx Pharmaceuticals' stock was trading at $3.78 at the beginning of the year. Since then, AMLX stock has increased by 295.5% and is now trading at $14.95.

How were Amylyx Pharmaceuticals' earnings last quarter?

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) announced its earnings results on Thursday, August, 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.02.
Read the conference call transcript.

When did Amylyx Pharmaceuticals IPO?

Amylyx Pharmaceuticals (AMLX) raised $190 million in an IPO on Friday, January 7th 2022. The company issued 10,000,000 shares at a price of $18.00-$20.00 per share.

Who are Amylyx Pharmaceuticals' major shareholders?

Top institutional shareholders of Amylyx Pharmaceuticals include Voya Investment Management LLC (0.01%). Insiders that own company stock include Morningside Venture Investment, Joshua B Cohen, Justin B Klee, George M Milne Jr, James M Frates, Patrick D Yeramian, Camille L Bedrosian, Gina Mazzariello, Bernhardt G Zeiher and Daphne Quimi.
View institutional ownership trends.

How do I buy shares of Amylyx Pharmaceuticals?

Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Amylyx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amylyx Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), AUO (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 10/19/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AMLX
• CIK: 1658551
• Web: amylyx.com
• Phone: 617-682-0917
• Fax: N/A
• Employees: 200
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Amylyx Pharmaceuticals: $16.75
• High Price Target: $25.00
• Low Price Target: $8.00
• Potential Upside/Downside: +12.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$301.74 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -82.48%
• Return on Assets: -70.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.72
• Quick Ratio: 8.72

Sales & Book Value

• Annual Sales: $87.37 million
• Price / Sales: 15.26
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.40 per share
• Price / Book: 6.23

Miscellaneous

• Outstanding Shares: 89,170,000
• Free Float: 78,199,000
• Market Cap: $1.33 billion
• Optionable: Optionable
• Beta: -0.33